Cargando…

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours. uPAR is closely related to the invasion and metastasis of malignant tumours, plays important rol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Bing-Tao, Tian, Huan, Sun, Jing, Zou, Jun-Bo, Zhang, Xiao-Fei, Cheng, Jiang-Xue, Shi, Ya-Jun, Fan, Yu, Guo, Dong-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932206/ https://www.ncbi.nlm.nih.gov/pubmed/35303878 http://dx.doi.org/10.1186/s12967-022-03329-3

Ejemplares similares

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
por: Montuori, Nunzia, et al.
Publicado: (2016)

Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi
por: Hovius, Joppe W. R., et al.
Publicado: (2009)

Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
por: Mauro, Concetta Di, et al.
Publicado: (2017)

Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention
por: Leth, Julie Maja, et al.
Publicado: (2021)

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style
por: Margheri, Francesca, et al.
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013)

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives
por: Skovgaard, Dorthe, et al.
Publicado: (2016)

Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer
por: Illemann, Martin, et al.
Publicado: (2014)

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography
por: Zhao, Baoyu, et al.
Publicado: (2015)

Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis
por: Shmakova, Anna A., et al.
Publicado: (2022)

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines
por: Hasanuzzaman, Mohammad, et al.
Publicado: (2007)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2022)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
por: Peng, Luogen, et al.
Publicado: (2023)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
por: Metrangolo, Virginia, et al.
Publicado: (2021)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma
por: Semina, Ekaterina V., et al.
Publicado: (2020)

Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group
por: Sorio, Claudio, et al.
Publicado: (2011)

Author Correction: Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2023)

Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR)
por: Ye, Yao, et al.
Publicado: (2020)

The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells
por: Lejeune, Danielle, et al.
Publicado: (2006)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
por: Sharma, Shailza, et al.
Publicado: (2021)

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
por: Harel, Efrat T., et al.
Publicado: (2019)

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
por: Christensen, Anders, et al.
Publicado: (2017)

Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR)
por: Elhussieny, Ahmed, et al.
Publicado: (2021)

Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis
por: Alpízar-Alpízar, Warner, et al.
Publicado: (2020)

Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs
por: Chang, Yu-Ching, et al.
Publicado: (2023)

Integrin is on uPAR to unleash cells
por: LeBrasseur, Nicole
Publicado: (2003)

uPAR's signaling two step
por: Leslie, Mitch
Publicado: (2007)

uPAR: An Essential Factor for Tumor Development
por: Lv, Tao, et al.
Publicado: (2021)

Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR–β1 integrin complex in colon cancer cells
por: Ahmed, N, et al.
Publicado: (2003)

Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221
por: Falkenberg, Natalie, et al.
Publicado: (2015)

The uPAR System as a Potential Therapeutic Target in the Diseased Eye
por: Cammalleri, Maurizio, et al.
Publicado: (2019)

The uPA/uPAR system in astrocytic wound healing
por: Yepes, Manuel
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d7e4ds3d5ershd57mph29f624m